1. DOP36 Vedolizumab-treated IBD patients show an increased gut microbial diversity associated with a specific serum metabolic signature. (30th January 2023) Authors: Pisani, L F; Crespi, G; Mellai, M; Flavio, C; Annunziata, M L; Manfredi, M; Luca, P; Porta, C Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i99 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗